drugset / Trial / NCT05573373
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study was to investigate the efficacy and safety of pamiparib in patients with EGFR-TKIs-resistant NSCLC, using a single-center, dual-arm, open-label design.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2024-11-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamiparib | Small molecule | 40 mg | — |